Acasa > Reviste de specialitate > Oncolog-Hematolog.ro > Provocări în tratamentul multimodal adjuvant/neoadjuvant al cancerelor rectale avansate local. Prezentare de caz

Provocări în tratamentul multimodal adjuvant/neoadjuvant al cancerelor rectale avansate local. Prezentare de caz

 Challenges in the neoadjuvant/adjuvant multimodal treatment in locally advanced rectal tumors. Case report

Conf. dr. Dana Lucia Stănculeanu, Daniela Zob, Raluca Ioana Mihăilă, Mihnea Alecu, Alexandru Dan Straja, Conf. dr. Daniela Moşoiu, Alexandru Grigorescu, Laurenţiu Simion

First published: 03 martie 2017

Editorial Group: MEDICHUB MEDIA

Abstract

The incidence of colorectal cancer in the European Union is in continuous growth and approximately 15% of the cases present with a hereditary component, the most frequently encountered associations being with the Lynch syndrome and familial adenomatous polyposis. Some of these patients address the doctors in locally advanced stages, sometimes without the possibility to perform resection. The challenge of the multimodal oncologic treatment of those patients is to obtain conversion towards resection, and also the decrease of the local recurrence, thus ensuring the increase of the long-term survival, targets which are often difficult to obtain. We present the case of a 54-year-old patient with locally advanced rectal cancer, who benefitted from multimodal treatment: neo-adjuvant chemotherapy and radiotherapy, and also from surgical intervention.
 

Keywords
locally advanced rectal tumor, multimodal treatment, neo-adjuvant treatment

Rezumat

Incidenţa cancerului rectal în Uniunea Europeană este în continuă creştere, aproximativ 15% din cazuri prezentând o componentă ereditară, cele mai frecvente asocieri fiind cu sindromul Lynch şi polipoza adenomatoasă familială. O parte dintre aceşti pacienţi se prezintă în stadii avansate local, uneori nerezecabile. Provocarea tratamentului oncologic multimodal al acestor pacienţi este de a obţine conversia către rezecabilitate, precum şi scăderea incidenţei recurenţei locale, asigurând astfel creşterea supravieţuirii la distanţă, deziderate ce sunt adesea greu de obţinut. Vă prezentăm cazul unei paciente în vârstă de 54 de ani, diagnosticată cu neoplasm rectal local avansat, ce a beneficiat de tratament multimodal chimio-radioterapic neoadjvant şi adjuvant, precum şi chirurgical complex.
 

Cuvinte cheie
tratament neoadjuvant rectal tumors

Bibliografie

1. NCCN guidelines version 3.2015-rectal cancer (http://www.nccn.org)
2. B. Glimelius et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology 24 (Supplement 6): vi81–vi88, 2013, doi:10.1093/annonc/mdt240 
3. http://www.ascopost.com/issues/april-10,-2015/colorectal-cancer-is-significantly-increasing-among-younger-adults-and-being-diagnosed-at-later-stages.aspx 
4. http://www.ascopost.com/issues/march-25,-2015/optimal-timing-of-rectal-surgery-60-days-or-less-post-chemoradiation-therapy.aspx 
5. http://www.ascopost.com/issues/january-25,-2015/colorectal-cancer-2015.aspx 
6. http://www.ascopost.com/issues/july-25,-2014/benefit-confirmed-for-adjuvant-oxaliplatin-in-rectal-cancer.aspx 
7. Ciara R Huntington, et al. Optimal timing of surgical resection after radiation therapy in locally advanced rectal adenocarcinoma: An analysis of the National Cancer Database (NCDB), J Clin Oncol 33, 2015 (suppl 3; abstr 510).
8. Yanhong Deng, et al. A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results, J Clin Oncol 33, 2015 (suppl; abstr 3500).
9. Joshua Smith et al. Advances and Challenges in Treatment of Locally Advanced Rectal Cancer, April 27, 2015, doi: 10.1200/JCO.2014.60.1054.
10. Chau et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer, J Clin Oncol. 2006 Feb 1; 24(4):668-74.
11. M. Wasif Saif. Managing Bevacizumab-Related Toxicities in Patients with Colorectal Cancer, MD, J Support Oncol 2009; 7:245–251.
12. Shenhong Wu et al. Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients, J Am Soc Nephrol. 2010 Aug; 21(8): 1381–1389.
13. Ju HJ, Lin JK, Chen WS, Jiang JK, Yang SH, et al. The Prognostic Role of Para-Aortic Lymph Nodes in Patients with Colorectal Cancer: Is It Regional or Distant Disease, (2015). PLoS ONE 10(6): e0130345. doi:10.1371/journal.pone.0130345.
14. G Cserni et al. Nodal staging of colorectal carcinomas and sentinel nodes, J Clin Pathol. 2003 May; 56(5): 327–335.
15. Tomonori M. et al., Complete Response of Isolated Para-aortic Lymph Node Recurrence from Rectosigmoid Cancer Treated by Chemoradiation Therapy with Capecitabine/Oxaliplatin plus Bevacizumab: A Case Report, Case Rep Oncol. 2012 May-Aug; 5(2): 216–221.
Citeşte mai mult

Articole din ediţiile anterioare

BREAST CANCER | Ediţia 3 / 2015

Terapia anti HER-2 în cancerul sânului, o scurtă privire asupra opţiunilor terapeutice disponibile

Dan Ilie-Damboiu

În această prezentare voi detalia noile terapii disponibile pentru tratarea cancerului de sân cu supraexpresie HER-2 (o oncogenă a familiei EGFR - ...

24 octombrie 2015